The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
This study has been completed.
To Learn More Contact
Study Contact at 844-434-4210 or JNT.CT@sylogent.com
ClinicalTrials.gov identifier: NCT03517722.